COVID-19 Trials and Studies

Volunteers Are Critical to COVID-19 Studies

Fred Hutch is conducting a number of therapeutic and non-therapeutic COVID-19 studies including treatment trials, observational studies and vaccine trials. To end this pandemic, we need volunteers of all ages, races, ethnicities and backgrounds to participate in research studies. That includes volunteers who have had a COVID-19 diagnosis and those who have never had a COVID-19 diagnosis.

The following studies and trials are currently enrolling participants. Participants may be eligible to enroll in certain studies concurrently. If you are unsure, please contact us to learn more.



Treatment Trials  |   Observational Studies   |  Vaccine Trials

young woman going through a medical exam in doctor's office

Treatment Trials

Fred Hutch researchers are conducting studies using investigational therapeutics to identify promising treatments for people diagnosed with COVID-19. These studies are researching autoimmune disease drugs, antiviral drugs and antibodies that may fight COVID-19.

Participants in observational studies may provide researchers with data and information through questionnaires, medical exams or other tests.

Trials Open For Enrollment

VIR-7831 - VIR Biotechnology, Inc.

A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized patients. The study is testing an infusion of VIR-7831 monoclonal antibody against SARS-CoV-2 to determine whether it can decrease the rate of progression. The antibodies in this study cannot give you SARS-CoV-2.

STOP COVID 2 – Washington University in St. Louis

A randomized, double-blinded, placebo-controlled study to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. The study will include participants with COVID-19 that are experiencing at least one related symptom, with adults that are 18-39 years of age required to have at least 1 risk factor for progression.

REGN-COV2 - Regeneron Pharmaceuticals

This trial will test the safety, tolerability, and efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With SARS-CoV-2 Infection. The REGN 2067 study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: (1) decrease the amount of virus in the body; (2) decrease the length of time the virus is in the body; and (3) decrease the length and severity of COVID-19 illness. The antibodies in this study cannot give you SARS-CoV-2.

Remdesivir - Gilead Sciences

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting. The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of hospitalization or death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.

young woman undergoing a nasal swab

Observational Studies

Fred Hutch researchers are conducting observational studies of people who are at risk for or have been diagnosed with COVID-19. These studies may observe the effect of a risk factor, a diagnostic test, a treatment or other interventions. The data collected can help advance understanding of how the disease progresses as well as its causes.

Participants in observational studies may provide researchers with data and information  through questionnaires, medical exams or other tests.

Studies Open For Enrollment


Fred Hutch's Dr. Michael Boeckh is leading CovidWatch, a Seattle-area study is investigating the infection rate of SARS-CoV-2 and its spread by recruiting people 18 years or older and in generally good health who have been exposed to coronavirus or work in an environment with a high risk of exposure.

Seattle Coronavirus Assessment Network (SCAN)

Stopping the COVID-19 pandemic requires a better understanding of how the disease spreads. The SCAN study provides free at-home testing for COVID-19. The findings will help the research partners, including Public Health — Seattle & King County, to keep people informed and make data-driven decisions on how to protect the community.

doctor administering a vaccination to a patient

Vaccine Trials

Fred Hutch is working with the National Institutes of Health and others to design human clinical trials for the most promising vaccine candidates developed by industry partners. These candidates must pass three phases of human testing to ensure they are safe and effective in preventing a disease. Typically, a vaccine is tested on healthy individuals.

Participants in a vaccine trial can expect to be carefully evaluated prior to receiving a vaccine and then closely monitored.

Trials Open For Enrollment

COVID-19 Prevention Trials Network

Fred Hutch is the operations center for the nationwide COVID-19 Prevention Trials Network (CoVPN). The CoVPN is conducting Phase 3 vaccine studies and is currently recruiting participants from across the U.S. to join the studies.

Patient Katrina Freeman at the Seattle Cancer Care Alliance
Patient Katrina Freeman at the Seattle Cancer Care Alliance Photo by Robert Hood / Fred Hutch

Clinical Trials for Immune Compromised Patients

Fred Hutch researchers developing guidelines to help physicians with the diagnosis and management of COVID-19 in hematopoietic and cellular therapy patients, and continue to develop best practices for managing cancer care during the COVID-19 pandemic. These efforts include developing and implementing infection and environmental control policies, coordinating institution-wide efforts, outpatient considerations, treatment decisions, ethical considerations, hospital management of oncology patients, and employee and leadership well-being.

Coronavirus Research

Fred Hutch is an important part of the international scientific response to the pandemic — tracking and modeling the virus' spread, developing diagnostic tests, designing vaccine trials, and working to prevent future outbreaks.

Our COVID-19 Research
Dr. Jesse Bloom standing in front of a whiteboard displaying scientific notations

Our COVID-19 Researchers

Our scientists are applying decades of expertise in the laboratory for solving disease problems and the development of new prevention and treatment options.

Meet Our Scientists
Research technician working on COVID-19 in Julie McElrath's lab

How Vaccines are Developed

Our researchers are working to develop a safe and effective vaccine for COVID-19. The process involves intense laboratory efforts and testing.

Our Vaccine Research
Last Modified, February 02, 2021